Breakthrough in breast cancer surgery without disfigurement

Chicago, June 15 (IANS) Serious tissue damage and disfigurement are a major fallout of most cancer therapies, but the one for breast cancer in particular has life-altering impact on women. Chicago-based Ananda Chakrabarty, a world-renowned pioneering biotech scientist, and Washington-based Susan Finston, a veteran of the biotech industry, together believe they are potentially close to resolving this major medical challenge.

Finston passionately talks about the experimental Amrita Breast Cancer Device (ABCD), created by Chakrabarty, and how it has what it takes to deliver locally targeted cancer therapy to the tumour.

"Our therapeutic approach may provide an important alternative or adjunct to surgery, radiation or chemotherapies that is designed to be non-toxic to healthy cells/tissues in the body," said Finston, who co-founded Ahmedabad (India)-based Amrita Therapeutics, with Chakrabarty, in an interview to Hi India newspaper here.

Dividing time between Washington and Ahmedabad, Finston has recently embarked on the independent funding platform Indiegogo where individuals invest modest amounts of money in various projects.

Excerpts from the interview:

Q: Describe Amrita's breast cancer device in a manner that a lay cancer patient can understand.

A: The experimental Amrita Breast Cancer Device (ABCD) is designed to provide safe, locally targeted cancer therapy directly to the breast cancer tumour, not affecting healthy breast tissue or the rest of the body, and delivered at the site of the tumour. Our therapeutic approach may provide an important alternative or adjunct to surgery, radiation or chemotherapies that is designed to be non-toxic to healthy cells/tissues in the body.

Q: At what stage are you in terms of pre-clinical data? When do you intend completing pre-clinical trials?

A: ABCD is the first therapeutic cancer device to utilise drug-eluting technology and requires pre-clinical testing and evaluation as both an anti-cancer drug and a therapeutic device. We hope to complete pre-clinical testing by the end of 2013, funds permitting, and have a number of interested partners interested in clinical development.

Q: Who has developed the device? What is its genesis?

A: Chakrabarty was inspired to invent the ABCD after learning of a patient whose cancer was kept in check - accidentally - through a catheter inserted adjacent to a cancer tumour for a totally different purpose. Ananda then invented the ABCD as a way to deliver safe and locally targeted cancer therapy though use of a drug-eluting device.

Q: What makes you think that your device has the potential to revolutionize cancer therapy?

A: ABCD can revolutionise cancer therapy by being the first of its kind. As mentioned, there is no drug-eluting device that is used for breast or other cancer therapy. For the last century, breast cancer patients have had to rely on disfiguring surgery, radiation and/or chemotherapies - carrying substantial health risks and possible side-effects as debilitating as the cancer itself.

In contrast, ABCD represents a revolutionary advance for breast cancer patients as a meaningful adjunct or alternative to surgery, radiation and chemotherapies, using well-understood drug-eluting stent technologies re-purposed for oncology therapy and using anti-cancer weapons with demonstrated effectiveness.

Q: What kind of challenges do you anticipate before you reach the FDA?

A: There are natural challenges associated with bringing the first device of its kind to the patient. We are engaging early on with FDA regulators on both the device and drug side of the house to ensure that we understand the evolving regulatory roadmap and have the smoothest possible transition from pre-clinical to clinical research.

Q: Are you looking at something akin to a stent?

A: That is exactly right - we are using drug-eluting technologies to deliver effective anti-cancer therapy by inserting the ABCD adjacent to the tumour site. It may be used as an adjunct to surgery, radiation and chemotherapies.

Q: When you speak of minimizing the invasiveness of chemotherapy are you talking in terms of inserting this device with some kind of coating the way a stent has?

A: Exactly right - the drug-eluting device delivers the cancer therapy to the tumour site.

Q: From this point to your device being available for regular use by cancer patients, what kind of time frame are you talking about?

A: We would hope to be able to start clinical trials with cancer patients within 12-18 months from completion of pre-clinical trials. Then it will depend on whether it may be possible to gain FDA support for priority consideration based on early clinical experiences.

Q: Do you have the best case scenario pricing in mind for your device?

A: We are hoping that this can be a low-cost medical device to bring cancer therapy to the average patient and cost should not be a barrier to access, all things considered.

(Mayank Chhaya can be contacted at m@mayankchhaya.net)

Matches

MORE TOP STORIES TODAY

Royal test for Kings

Royal test for Kings

Preview — Clash of philosophies between Australia-centric teams More »

Duminy steals first win for Delhi

Duminy steals first win for Delhi

Furious fifties by Duminy and Dinesh Karthik end a long losing streak for the Daredevils. More »

AB, Parthiv seal Bangalore's second win

AB, Parthiv seal Bangalore's second win

Royal Challengers overcame a stutter to cruise to the small target they were set by Mumbai Indians. More »

‘Felt like helpless minority’

‘Felt like helpless minority’

Former BCCI treasurer Ajay Shirke says emotions got the better of the Srinivasan and he tried to oversimplify things by calling Meiyappan an “enthusia… More »

Glenn Maxwell carves his parallel universe

Glenn Maxwell carves his parallel universe

Glenn Maxwell seems to project an icy disdain when at the crease. Match situations rarely faze him and the bubble in which he plays excludes everyone … More »

No way back for Pietersen: ECB

No way back for Pietersen: ECB

Kevin Pietersen's hopes of reviving his international career appeared to end Saturday when ECB managing director Paul Downton said there was 'no way back'… More »

Srinivasan can attend BCCI meeting

Srinivasan can attend BCCI meeting

His status as president of TNCA makes him eligible to attend the Working Committee meeting on Sunday. More »

The world record that nearly wasn't

The world record that nearly wasn't

Twenty years ago this week, Brian Lara became Test cricket's highest scorer, but he almost didn't make it. More »

Moores gets second stint as coach

Moores gets second stint as coach

In a two-year spell from 2007 to 2009, the 51-year-old Moores led England in seven Test series. More »

BCCI is not anybody’s property — Dalmiya

BCCI is not anybody’s property — Dalmiya

Dalmiya feels that Srinivasan’s ‘power hungry’ attitude isn’t helping matters. More »

Tough for bowlers: Saeed Ajmal

Tough for bowlers: Saeed Ajmal

The 36-year-old believes the T20 format and rule changes in 50-over matches have made a real difference. More »

Bangladesh senior players to see shrink

Bangladesh senior players to see shrink

Bangladesh's senior players will have three sessions with a psychological skill development coach later this month More »

KP ridicules idea of day-night Tests

KP ridicules idea of day-night Tests

Kevin Pietersen has ridiculed the idea of day-night Test cricket, saying the game would be so different to proper Test cricket that we will need a whole… More »

Rajasthan edge low-scoring thriller

Rajasthan edge low-scoring thriller

The bowlers restricted Hyderabad to 133 for 6 before Rahane and Binny took Rajasthan over the line. More »

BCCI members want independent probe

BCCI members want independent probe

The board members are realising after the Supreme Court's observations that something has to be done — IS Bindra More »

Maxwell blitz takes Punjab home

Maxwell blitz takes Punjab home

The Kings XI batsman blasted a 43-ball 95 to help his team pull off a massive chase against Chennai Super Kings. More »

'BCCI lacks leaders to take on Srini'

'BCCI lacks leaders to take on Srini'

Two former BCCI presidents, Shashank Manohar and Jagmohan Dalmiya, have reacted strongly to the news of the BCCI calling an emergent meeting on Sunday… More »

Delhi look for first points against confident Kolkata

Delhi look for first points against confident Kolkata

Preview — The threat of Sunil Narine looms large again. More »

Bangalore vs Mumbai: A battle of the big-hitters

Bangalore vs Mumbai: A battle of the big-hitters

Preview — Given the firepower in both line-ups, Dubai crowd may see another high-scorer More »

Yuvraj tees off to Sharjah's delight

Yuvraj tees off to Sharjah's delight

Yuvraj Singh was hardly convincing to begin with against Delhi, but a big dose of crowd support and a helping of poor bowling meant he had the opportunity… More »

Stressed Trott stands down again

Stressed Trott stands down again

The England and Wales Cricket Board (ECB) on Friday confirmed that batsman Jonathan Trott is to take another break from all cricket with immediate eff… More »

PCB starts another coach hunt

PCB starts another coach hunt

The PCB has decided to not extend the contracts of head coach Moin Khan, fielding coach Shoaib Mohammad and batting consultant Zaheer Abbas, and has invited… More »

Fiery star Stokes bids to curb his temper

Fiery star Stokes bids to curb his temper

England all-rounder Ben Stokes admits he must keep his anger under control if he is to end his international exile. More »

Bangalore's arsenal blazes to victory

Bangalore's arsenal blazes to victory

Yuvraj Singh was back to his best in his first match for Royal Challengers Bangalore. More »